Navigation Links
Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients
Date:9/2/2014

SAN CARLOS, Calif., Sept. 2, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has entered into an Exclusive Channel Collaboration (ECC) with Sanofi Chimie, a wholly owned subsidiary of Sanofi (EURONEXT: SAN and NYSE: SNY) to develop an enhanced production process for a specific family of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi's current manufacturing operations in France. This collaboration will leverage Intrexon's proprietary technology suite plus Sanofi's expertise and innovation in yeast metabolism and industrial chemistry to increase overall yield.

Under the ECC, Intrexon will utilize its advanced computational biology and bioinformatics to identify the most efficient biological pathways for producing these marketed APIs.  Intrexon's Industrial Product Division facilities in Hungary and California will design and synthesize new components tailored to drive optimal output from constructed cell lines leading to improved process economics.  Furthermore, for faster, more efficient collaboration, Intrexon intends to provide ECC partners like Sanofi the ability to remotely access its extensive library of characterized genetic components facilitating customized gene design and high-throughput modular DNA assembly via its new BeyondBio™ platform. 

"We are excited to partner with Sanofi to improve existing fermentation processes, providing a competitive advantage in marketed APIs production," said Randal J. Kirk, Intrexon Chairman and Chief Executive Officer. "We are confident that our synthetic biology expertise and robust technology platforms will drive development of Sanofi's next-generation strain in a commercially feasible way that also produces the highest possible yields."

About Intrexon Corporation

Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Consumer, Food, Energy, and Environment Sectors to create biologically-based products that improve the quality of life and the health of the planet.  Through the company's proprietary UltraVector® platform and suite of technologies, Intrexon provides its partners with industrial-scale design and development of complex biological systems.  The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells.  We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at www.DNA.com.

Trademarks

Intrexon, BeyondBio, UltraVector, and Better DNA are trademarks of Intrexon and/or its affiliates.  Other names may be trademarks of their respective owners.

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements.  These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information contact:

Intrexon Corporation Contacts:
Marie Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850
publicrelations@intrexon.com

Investor Contact:
Christopher Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052
Investors@intrexon.com

 


'/>"/>
SOURCE Intrexon Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Intrexon Announces Third Quarter Financial Results
2. Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
3. Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company
4. Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection
5. Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine
6. Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial
7. CannaMed Announces Name Change and Trading Symbol Change
8. SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP
9. Mast Therapeutics Announces Management Change
10. Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer
11. PMDS Announces New Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2020)... ... , ... Federal data has already confirmed that most of the deadly victims ... failing to report that many of those who have died from the virus were ... new song by an artist that calls himself The Undiscovered Artist brings light to ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... ... Newton Design, responded in mid-March 2020 to deliver thousands of critical Personal Protection ... Pivoting rapidly from their usual aerospace production work, the three companies teamed together ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... donated its second COVID-19 drive-through testing shelter in Camden County, New Jersey. The ... Freeholders and Connor Strong & Buckelew and is located at 3100 Federal Street, ...
Breaking Medicine Technology:
(Date:5/21/2020)... ... May 21, 2020 , ... ESO , the ... today announced the findings of its 2020 ESO Fire Service Index . The ... calls versus fire-related calls, first apparatus turnout time and travel time, the most common ...
(Date:5/21/2020)... Va. (PRWEB) , ... May 21, 2020 , ... A ... and Medicine Group, details over 90 companies involved in the point of care ... many hospital facilities for preliminary testing, COVID-19 has made point-of-care more important than in ...
(Date:5/16/2020)... ... 15, 2020 , ... For patients who have gone to see Andy Gaertner, D.M.D , ... always had in place. After being allowed to re-open during the current pandemic, they have ... are as safe and comfortable as possible while going through their dental exams and treatments. ...
(Date:5/16/2020)... ... ... Dr. Tomasz Biernacki states that “If bunion and flat foot formation ... keep the foot from being unable to fit into good supportive shoes in the ... flat feet and bunion formation can have further knee pain, hip pain ...
(Date:5/15/2020)... HOLTSVILLE, N.Y. (PRWEB) , ... May 15, 2020 ... ... management and risk management solutions, recently announced the company and its healthcare-focused background ... of the Top 10 Pre-Employment Screening Consulting/Services Companies 2020. A distinguished panel comprising ...
Breaking Medicine News(10 mins):